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Summary 
Systemic and localized inflammation elicit a number of host responses which include fever, cachexia, 
hypoglycemia, and major changes in the concentration of liver plasma proteins. Interlenkin 6 
(IL-6) is considered an important mediator of the inflammatory response,  together with IL-1 
and tumor necrosis factor c~ (TNF-c  0. The purpose of this study was to unequivocally determine 
the role of IL-6 in these phenomena making use of IL-6-deficient mice that we have recently 
generated by gene targeting. We report here that in the absence of IL-6, mice are unable to 
mount a normal inflammatory response to localized tissue damage generated by turpentine injection. 
The induction of acute phase proteins is dramatically reduced, mice do not lose body weight 
and only suffer from mild anorexia and hypoglycemia. In contrast, when systemic inflammation 
is elicited through the injection of bacterial lipopolysaccharide (LPS), these parameters are altered 
to the same extent both in wild-type and IL-6-deficient mice, demonstrating that under these 
conditions IL-6 function is dispensable. Moreover, we show that LPS-treated IL-6-deficient mice 
produce three times more TNF-c~ than wild-type controls, suggesting that increased TNF-c~ 
production might be one of the compensatory mechanisms through which a normal response 
to LPS is achieved in the absence of IL-6. We also show that corticosterone is normally induced 
in IL-6-deficient mice, demonstrating that IL-6 is not required for the activation of the hypothahmic- 
pituitary-adrenal  axis. Our results reinforce the idea that different patterns of cytokines are involved 
in systemic and localized tissue damage, and identify IL-6 as an essential mediator of the inflammatory 
response to localized  inflammation. 
cute inflammation results in a general reaction of the or- 
ganism which include anorexia,  loss of body weight, 
hypoglycemia, and changes in the serum levels of several plasma 
proteins produced by the bepatocytes, the so-called liver acute 
phase response (APR)  1 (1). Several stimuli of different origin 
such as bacterial  infection, endotoxemia and sterile  tissue 
damage (burns, surgical traumas, ischemic necrosis) can trigger 
the host inflammatory response (1). These conditions can be 
reproduced by a number of experimental treatments. In par- 
ticnlar, intraperitoneal injection of bacterial endotoxin (LPS), 
a component of the Gram negative bacterial  wall, is com- 
monly used to reproduce systemic inflammation, and subcu- 
1 Abbreviations used in this paper: AGP, r  glycoprotein;  c~2M, o~2 
macroglobulin;  APP, acute phase protein;  APR, acute phase response; 
CNTF, ciliary neurotrophic  factor; CS, corticosterone; Hp, haptoglobin; 
HPA,  hypothalamic-pituitary-adreual;  Hpx,  hemopexin;  LIF, leukemia 
inhibitory factor; OM, oncostatin M; SAA and P, serum amyloid A and P. 
taneous injection of turpentine causes the formation of sterile 
abscesses and therefore peripheral tissue damage (2). 
Several cytokines, and primarily IL-1, TNF-c~,  and IL-6, 
are known to be involved in the regulation of these phenomena, 
although their spedfic roles in the various aspects of inflam- 
mation and in the response to the different stimuli are not 
yet fully clarified.  TNF-ct is rapidly and strongly induced 
by LPS, and is thought to play a major role in lethality fol- 
lowing endotoxin shock (3-5). However, it is not produced 
as a consequence of a turpentine abscess (6).  Conversely, 
production of IL-1 and IL-6 is induced in response to both 
inflammatory stimuli (7, 8), and experiments with neutralizing 
antibodies have shown that inhibition of the activity of ei- 
ther of these cytokines results in the reduction of a number 
of systemic reactions to inflammation (7-9).  With respect 
to the regulation of the liver APR, the acute phase protein 
(APP)  genes have been divided into two classes according 
to their response to different cytokines (10). Class 1 genes, 
which include haptoglobin (Hp), hemopexin (Hpx), cd-acid 
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SAP), are induced by IL-1 and TNF-ot,  either  alone or in 
combination with IL-6. In contrast class 2 genes, which in- 
dude o~l-antichymotrypsin,  fibrinogen, and o~2-macroglobulin 
(c~2M), respond to IL-6 alone. Interestingly,  it has been re- 
cently shown that a family of cytokines related to IL-6, namely 
leukemia inhibitory factor (LIF), oncostatin M  (OM),  IL- 
l1, and ciliary neurotrophic factor (CNTF),  are able to in- 
duce the same spectrum of acute phase genes as IL-6 in he- 
patic cells (11 and references therein), suggesting functional 
redundancy. 
Corticosteroid hormones participate in the induction of 
most APPs, being required for their optimal induction (12). 
Both  LPS  and  turpentine  are  able  to  rapidly  induce  cor- 
ticosterone  production  through  the  activation  of  the 
hypothalamic-pituitary-adrenal (HPA) axis and the induction 
of ACTH (7, 13, 14). IL-1 is known to be one of the main 
mediators of this induction,  as IL-1 blocking antibodies or 
IL-1  receptor  antagonist  can  block  the  ACTH  and  cor- 
ticosterone response to LPS (15, 16); IL-6 has been proposed 
to be able to synergize with IL-1 to generate maximal re- 
sponse (17). Corticosteroids exert in turn an inhibitory effect 
on the production of inflammatory cytokines, activating thus 
a negative feedback loop (18-20). 
We have recently described the generation of IL-6-ddident 
mice by gene targeting, and showed that they are viable and 
fertile (21). Here we show that the complete absence of IL-6 
abolishes or dramatically reduces several aspects of the acute 
host response to turpentine,  including the liver acute phase 
reaction, anorexia, loss of body weight, and hypoglycemia. 
However, the same responses are only slightly modified after 
LPS treatment, indicating that in this case functional redun- 
dancy between different cytokines can compensate for IL-6 
loss of function. 
Materials  and Methods 
Animals and Treatments.  8-10-wk-old  IL-6-/-  and  +/+  mice 
bred in our barrier facility were used. The generation and genetic 
background  of these mice was described recently (21). Mice were 
maintained in standard conditions under a 12-h light-dark cycle, 
provided irradiated food (4RF21; Mucedola SILL; Settimo Mihnese, 
Milan, Italy) and chlorinated water ad libitum. Procedures involving 
animals and their care were conducted in conformity with national 
and international hws and policies (EEC Council Directive 86/609, 
OJ L 358, 1, December 12, 1987; Italian Legishtive Decree 116/92, 
Gazzetta Ufficiale della Repubblica Italiana No. 40, February 18, 
1992; National  Institutes  of Health Guide for the Care and Use 
of Laboratory Animals, NIH publication  No. 85-23, 1985). LPS 
(From Escherichia coli serotype 026:B6) was purchased from Sigma 
Chemical Co. (St. Louis, MO), resuspended in sterile pyrogen-free 
saline solution and injected intraperitoneaily at a dose of I mg/kg 
body weight. Steam distilled turpentine  was injected subcutane- 
ously. A single injection of 100/~1 was given for the analysis of 
mP,  NAs, CS, TNF-o~, and Iblc~. Two injections, one over each 
hind limb, were given for the analysis of body weight, food intake 
and hematic glucose. Control mice were injected intraperitoneaily 
or subcutaneously with sterile pyrogen-free saline solution. Blood 
was collected from the retroorbital  cavity. 
RNA Expression.  At different time intervals after treatment, 
mice were killed by cervical dislocation and RNA was isolated by 
the guanidine isothiocyauate method (22) and subjected to Northern 
blot analysis as previously described (23). 32p-labeled cDNAs for 
rat ot2-M (24), mouse serum amyloid P (25), rat c~l-acidic glyco- 
protein (26), rat haptoglobin  (26), rat hemopexin (27), mouse al- 
bumin  (28),  and  mouse  GADPH  (29)  were  used  as  probes. 
Poly(A)*  mRNA  was  prepared  using  oligo d(T)  columns  (5 
Prime-3  Prime,  Inc.,  Boulder,  CO) and  hybridized  with  32p_ 
labeled rat o~2M and mouse GAPDH eDNA. The relative abun- 
dance of the different mRNAs was measured by densitometric scan- 
ning of the autoradiographs. 
Serum Protein Profile and Serum SAA Measurement.  Sera  were 
subjected to cellulose acetate dectrophoresis.  Strips were stained 
with Poncean red solution and densitometric  profiles were deter- 
mined. SAA was measured in serum samples using an ELISA assay 
as previously described (30). 
TNF, CS, andlL.lotMeasurement.  TNF-c~  bioactivity in serum 
samples was measured 1 h 30 min after LPS or turpentine  treat- 
ment by standard cytotoxieity assay using L929 ceils (31). CS was 
measured in the serum 1 h 30 rain after LPS or turpentine  treat- 
ment by a ILIA, using an antiserum to corticosterone obtained from 
Sigma Chemical Co. and following manufacturer's  instructions. 
[3H]Corticosterone  was  purchased  from  Amersham  Corp. 
(Arlington Heights, IL). IbloL was measured in the serum 2 h after 
LPS treatment  and 18 h after turpentine  treatment  using a mouse 
II,  lot ELISA kit purchased from Genzyme Corp. (Cambridge, MA) 
and following manufacturer's  instructions. 
Hematic Glucose.  Hematic ghcose level was determined using 
the automatic analyzer Ceil-Dyn 800 (Sequoia, Santa Barbara, CA). 
Body  Weight and Food lnta~  Measurements.  The  mice were 
weighed every 24 h starting  from the day and time of treatment 
(day 0). Food intake was measured for each group at the same time 
intervals and mean food intake per mouse per day was calculated. 
StatisticalAnalysis.  Comparisons of mean values  were performed 
by Student's  t test for independent  samples. 
Results 
The Liver Acute Phase Response to LPS Injection Is Similar 
in IL-6-/-  and +/+ Mice.  To evaluate the specific role of 
IL-6 in the LPS induced liver APR, LPS was injected into 
IL-6-defident  (IL-6- / - ) mice or wild-type (IL-6 + / +) age 
matched controls, the mice were killed at different time in- 
tervals, and total liver RNA was extracted. The mR.NA levels 
for several positive APPs, as well as for albumin,  a negative 
acute phase reactant,  were evaluated by Northern blot.  As 
shown in Fig. 1, the changes of most mR/qAs analyzed were 
comparable in the mutant  and wild-type mice.  After nor- 
malization with the internal control, the extent of albumin 
decrease was identical,  and only minor differences were no- 
ticed in the induction of Hpx, HI), and AGP. However, SAP 
mRNA was induced considerably less in the IL-6-/-  mice, 
and no induction of the c~2M mRNA was detected. Interest- 
ingly, when measured 18 h after LPS treatment, SAP mRNA 
levels  were only two-  to  threefold  lower in  the  IL-6-/- 
mice than in the IL-6 + /+  controls, but dropped to almost 
background levels at 24 h, suggesting that the most critical 
role played by IL-6 in the induction of this gene in response 
to LPS is probably to sustain its activation rather than to ini- 
tiate it.  These results suggest that,  as far as the liver APR 
is concerned, in systemic inflammation  the absence of IL-6 
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6-/-  and IL-6+/+ mice following  LPS treatment. Mice were treated 
with LPS (1 mg/Kg, i.p.), total liver R.NA  was extracted  at 0, 2, 18, and 
24 h after  the treatment  and hybridized  with the indicated  cDNAs. GAPDH 
was used as an internal control Alb, albumin. 
Figure 2.  Northern blots showing liver acute phase mRNA in IL- 
6-/-  and IL-6  +  /+ mice after turpentine treatment. Mice were treated 
subcutaneously  with 100/~1  of turpentine. Total  liver  RNA was extracted 
at the time intervals  indicated  and analyzed  as described  in the legend  to 
Fig. 1. 
can mostly be compensated for by other cytokines known 
to be induced by LPS like IL-1 and TNF-c~. 
Impaired Liver Acute Phase Response to Turpentine Injection 
in the IL-6-/-  Mice.  The reaction to turpentine of both 
IL-6-/-  and IL-6+/+ mice was analyzed essentially as de- 
scribed  for LPS. In this case, the difference in the levels of 
mRNAs encoding APPs after the treatment was dramatic 
(Fig.  2).  Whereas in  IL-6+/+  mice the various mtLNAs 
were induced between 9- and 30-fold, the maximal induc- 
tion in IL-6- / -  mice was about fourfold. Furthermore, in- 
duction started earlier in the IL-6 +  /+  than in the IL-6-/- 
mice, being already detectable 2 h  after treatment. Consis- 
tent with what was observed upon LPS treatment, the most 
dramatic difference was noticed for o~2M mRNA. Albumin 
mRNA levels did not decrease at all in the IL-6-/-  mice, 
confirming that IL-6 also plays an important role in the regu- 
lation of negative acute phase reactants, at least in this model 
of inflammation. These data confirm and extend the previous 
observation that monoclonal anti-IL-6 antibodies can block 
the serum accumulation of SAP in response to a turpentine 
abscess (9),  and imply that IL-6 plays a unique role in the 
regulation of the liver APR induced by localized tissue damage. 
The mRNA  Coding for the Class 2 APP ot2M Is Not In- 
duced in the IL-6-/- Mice  To confirm that neither LPS nor 
turpentine are able to induce the ot2M RNA in the IL-6-/- 
mice, we prepared polyA + RNA from the samples analyzed 
above and hybridized it with the ot2M probe. As shown in 
Fig. 3, cr  RNA was never  detectable in the liver from 
the IL-6-/-  mice, despite the strong induction occurring 
in the 1I.-6 +  /+  mice. Interestingly, the IL-6 related cyto- 
kines LIF, CNTF, OM,  and IL-11 have been shown to be 
able to induce several class 2 acute phase genes by themselves 
(11). Our results suggest however that under physiological 
conditions these cytokines are not able to compensate for the 
absence of IL-6, at least under the experimental conditions 
described. 
Serum Protein  Profiles  and Serum SAA.  Although the regu- 
lation of APP production is known to occur mostly at the 
transcription level (23, 32), posttranscriptional and/or post- 
translational effects have been described (33, 34). To evaluate 
if the alterations in mRNA induction observed  are reflected 
by equivalent changes in circulating plasma proteins, we ana- 
lyzed the protein profiles of sera from LPS- and turpentine- 
treated mice (Fig.  4 A). In IL-6+/+  mice both inflamma- 
tory stimuli caused a comparable decrease in the albumin peak 
and increase in the c~ and B globulin peaks,  which include 
most of the major APPs.  As a result, the ratio of albumin 
Figure  3.  a2M  expression in liver of IL.6-/-  and II.-6  §  mice. 
Poly(A)  § mRNA was prepared from the total RNA at the time points 
indicated  and analyzed  by Northern  blot as described  in the legend  to Fig. 1. 
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changes in 11"6-/-  and IL-6 + /  + 
mice after  LPS or turpentine treat- 
merit. Treatments were  performed 
as described  in the Materials and 
Methods section. (.4)  Serum  pro- 
tein profile  after  LPS and turpen- 
tine treatment. A/G is the ratio 
between  the areas occupied  by the 
albumin and globulins fraction, 
respectively.  (B) Serum  SAA levels 
measured by ELISA at the time 
points indicated. Black bars and 
open bars represent I1-6  +  / + and 
11-6-/- mice, respectively.  Data 
are shown as mean values _+ SD. 
(*) Significantly  different  from  IL- 
6+/§  <0.01. 
to globulin decreased by m50%. In contrast, turpentine treat- 
ment did not significantly modify the protein profile of the 
IL-6-/-  mice,  in  agreement  with  the results  obtained by 
Northern  analysis  and the albumin/globulin  ratio was un- 
changed, while in response to LPS treatment it decreased al- 
most  to the  same extent  as in  the  IL-6 +  /+  mice. 
To further extend these results, we measured serum SAA 
levels 18 and 24 h after LPS or turpentine injection. As shown 
in Fig. 4 B, SAA was undetectable in the serum of the tur- 
pentine  treated  IL-6-/-  mice,  while  its  levels  were  very 
high in the serum of IL-6 + / + mice at both time points ana- 
lyzed.  Interestingly,  in  the case of LPS injection  the SAA 
levels detected after 18 h were significantly lower in the IL- 
6-/-  mice  than  in  the  IL-6 +/+  controls.  This  difference 
was not maintained after 24 h, when SAA concentration had 
already started to drop. This phenomenon was not predicted 
from the kinetics of induction observed for the mKNAs. Since 
SAA is known to be regulated also posttranscriptionaUy (33), 
our results seem to suggest a role for IL-6 in the regulation 
of the liver APR also at  this  level. 
Corticosterone Induction Is  Normal in  the  IL-6-/-  Mice. 
Corticosteroid hormones are important  cofactors in the in- 
duction of AP genes, and their action is considered of partic- 
ular importance in the induction of the AGP and o~2M genes 
(35, 36). For these reasons we decided to measure serum cor- 
ticosterone (CS) both before and after turpentine or LPS treat- 
ment. As shown in Fig. 5 (A and B), both basal and induced 
CS levels were equivalent in IL-6-/-  and IL-6+/+  mice, in- 
dicating that the impaired induction of acute phase genes de- 
scribed above is not due to a secondary effect through a defec- 
tive CS induction. 
Induction of TNF-at and IL-1 in the IL-6-/-  Mice.  Both 
TNF-o~ and IL-1 are prominent cytokines involved in the regu- 
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lation of different aspects of the host response to inflamma- 
tion, and they are thought to exert at least part of their effects 
through the induction of IL-6 (37).  It was therefore impor- 
tant  to analyze their  levels  in  the  IL-6-/-  mice. 
Interestingly,  TNF-o~ induction by LPS was found to be 
approximatdy threefold higher in IL-6-/-  than in IL-6 +  /+ 
mice (P <0.05) (Fig.  5 C'). It was reported that IL-6 can in- 
hibit TNF-o~ transcription (38); our observation might there- 
fore be a consequence of the absence of this negative feed- 
back in the  IL-6-/-  mice.  Whatever  the mechanism,  the 
increased TNF-o~ levels might contribute to compensate for 
the absence of IL-6, at least for those acute phase genes known 
to be responsive to this cytokine. Confirming what was al- 
ready reported by others (6), we could not detect any TNF-cr 
activity after turpentine injection at the time points analyzed 
(data not  shown). 
In contrast to what was observed for TNF-c~,  there was 
no statistically significant  difference in the extent of IL-lc~ 
induction in the IL-6-/-  and IL-6 +  /+  mice (Fig. 5, D  and 
E). In both cases the absolute levels reached after turpentine 
injection (Fig.  5 E) were lower than after LPS treatment (Fig. 
5 D). The observation that IL-1 is induced normally in mu- 
tant  mice suggests that  also this cytokine may be involved 
in compensating  for IL-6 absence. 
Anorexia, Food Intake, and Hypoglycemia in  the IL-6-/- 
Mice.  It has been reported that antibodies against IL-6 par- 
tially blocked both LPS and turpentine induced weight loss 
and hypoglycemia (7-9). To test the effects of a complete ab- 
sence of IL-6 on these clinically important aspects of inflam- 
mation, we decided to measure these parameters in IL-6-/- 
mice. 
The measures of body weight, daily food intake and hematic 
glucose after LPS injection are shown in Fig. 6 (tt, B, and A 
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Figure  5.  Effects  of LPS and 
turpentine  on the induction of 
serum CS, TNF-a, and IDla in 
IL-6-/_ and ID6+/+ mice. Mice 
were treated as described in the 
text  with  LPS, turpentine,  or 
sterile saline solution as control. 
TNF-a and Ibla in the control 
mice were undetectable and were 
therefore  not  reported in  the 
graphic. (/1 and B) CS levels were 
measured by a ILIA in the serum 
1.5 h after treatment with turpen- 
(A, TUR~.) or LPS (B). B&/e 
bars and open bars repr--~-~ent IL, 
6 +  / + and Ib6-/- mice, respec- 
tively. (A) four mice/group; (B) 
seven mice/group. Data are shown 
as mean values + SD. (C) TNF~a 
was measured  by standard  cytotox- 
icity assay 1.5 h after LPS treat- 
ment  (seven mice/group);  (*) 
significantly different from II.-6 
+/+, p <0.05. (D and E) IDla 
was measured  by ELISA  2 h after 
LPS treatment (D), and 18 h after 
turpentine  treatment  (E). Nine 
mice/group  were  used.  The  differ- 
ences were not statistically sig- 
nificant. 
C, respectively).  All  three  parameters  decreased  equivalently 
in the IL-6+/+ and IL-6-/- mice, and body weight and 
food  intake  returned  to  normal values  3 d after  the  treatment. 
These  results  seem to  indicate  that  IL-6  action  is  not  required 
for  the  generation  of  these  host  responses  to  LPS, confirming 
that  an overall  normal inflammation process  in response to 
endotoxin can  take  place  in  the  absence  of  IL-6.  The response 
to  turpentine  was however completely different.  During the 
first  3 d after  treatment the body weight did not decrease 
at aU in the IL-6-/- mice,  while the IL-6  +  /+ mice lost  a 
considerable amount of weight (Fig. 7 A). In addition, d~ily 
food intake and glucose concentration decreased significantly 
less in IL-6-/-  than in IL-6 + /+  mice (Fig.  7,  B  and C). 
Surprisingly, whereas after 4 d  the IL-6+/+ mice started to 
regain weight and increase their food intake, both parameters 
started to drop dramatically in IL-6-/-  mice (Fig. 7, A  and 
B). One of them died at day 7, and all mice were killed at 
day 8 to avoid chronic effects of turpentine toxicity. We do 
not know the mechanism for the phenomenon described. 
Likely, the absence of an eitident response to the inflamma- 
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Figure 6.  Changes  in body weight, food intake, and hematic glucose after LPS treatment of IL-6-/- and IL-6  § / § mice (six mice/group). Mice 
were treated as described above. The values of body weight and food intake did not change in the control mice, and were therefore not reported. 
(/1) Body weight was measured every 24 h at the same time of the day starting from the day of treatment (day 0) until the mice regained the original 
weight (3 d); the mean values are indicated. (B) Cumulative food intake was measured for the different groups every  24 h and mean values for individuals 
were derived. (C) Hematic glucose was measured 4 h after treatment with LPS or pyrogen free saline solution. Black bars and o/an bars represent IL- 
6 +  /+  and ID6-/- mice, respectively. Data are shown as mean values e  SD. 
1247  Fattori et ai. A  B  C  ￿9  IL-6+/+ 
[]  IL-6-/_ 
=  9o  J  "  "o..~lL-6-//  0 
days  0  1  2  3  4  5  6  7  8  days  0  !  2  3  4  5  6  7  T 
SALINE  TURP. 
Figure 7.  Changes  in body weight, food intake, and hematic glucose  following turpentine treatment of IL-6-/- and IL-6  +  / + mice (six mice/group). 
Mice were injected subcutaneously  on both hind limbs with 100/zl of turpentine or with saline solution, and the values were calculated as described 
in the legend to Fig. 6. The values of body weight and food intake did not change in the control mice, and were therefore not reported. (/1, BODY 
WEIGHT) the mean values are indicated. Asterisks indicate a significative difference  between Ib6- / - and II.-6  +  / + mice ~ <0.001). (B, FOOD IN- 
TAKE) The mean values for individual animals were derived from cumulative food intake within the groups. (C) Hematic glucose  was measured 18 h 
after treatment with turpentine or pyrogen free saline solution. Black bars and o/an bars represent II~6  +  / + and II.-6-/-  mice, respectively.  Data are 
shown as mean values +  SD. (A) IL-6-/-  mice, saline versus turpentine, p <0.05. (*) Turpentine treated Ib6-/-  versus IL-6+/§ mice,  p <0.01. 
(**) Ib-6+/+ mice, saline versus turpentine, p <0.01. 
tory stimulus in the IL-6-/-  mice impairs tissue repair and 
recovery, implying that IL-6 action is beneficial in the host 
acute response to localized inflammation. 
Discussion 
The overall characteristics of the host response to inflam- 
mation  are  remarkably  similar,  whatever  the  triggering 
stimulus may be. However, different kinds of injury involve 
different cell types, and as a consequence the mediators pro- 
duced and their site of release  are different.  A  striking  ex- 
ample is the finding that endotoxin induces the synthesis of 
IL-6 by liver Koapffer cells, whereas sterile tissue damage does 
not (6). This difference is probably due to the fact that LPS 
rapidly enters the circulation, and can reach and directly stimu- 
late liver nonparenchymal  cells.  Another  important  differ- 
ence is that TNF-c~, a prominent cytokine in LPS-generated 
systemic inflammation,  is not produced in response to tur- 
pentine induced localized inflammation.  Distinguishing be- 
tween  the  specific  roles  the  different  mediators  play  in 
regulating  the inflammatory response has not been an easy 
task so far, due to the complex interactions between cytokines, 
glucocorticoid hormones, and their signal transmission path- 
ways, and to the lack of suitable genetic models. The interpre- 
tation of the results obtained by injecting in vivo recombinant 
cytokines is therefore not straightforward,  and experiments 
with blocking antibodies cannot be conclusive, both because 
a complete inactivation is diflficult to achieve and to demon- 
strate, and because monoclonal antibodies in particular against 
IL-6 have been shown to complex the cytokine and to in- 
crease its half-life (8, 9). Mutant mice generated through the 
targeted mutagenesis of the mouse genome may provide pre- 
cisely the opportunity required to obviate these problems by 
studying the inflammatory reaction in the complete absence 
of a given cytokine. 
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We have used IL-6-deficient mice generated by gene tar- 
geting to explore the specific functions of IL-6 in determining 
the host response of two fundamentally different types of 
injury, systemic inflammation, reproduced by means of LPS 
injection,  and localized inflammation,  mimicked by sterile 
turpentine abscesses. While this manuscript was in prepara- 
tion,  Kopf et al. (39) reported similar studies on indepen- 
dently derived IL-6--deficient mice. They found that the AP 
reactants Hp, AGP, and SAA are not induced by sterile tissue 
damage or by infection with Gram positive bacteria in the 
mutant mice, whereas the induction of these genes and pro- 
teins is almost normal after LPS injection. Our results confirm 
their findings; however, we could identify at least one specific 
defect in the response to LPS, that is the lack of induction 
of the c~2M mRNA in the IL-6-/-  mice. Moreover, we ex- 
plored several aspects of the host reactions to localized i,fl2tu- 
marion in addition to the liver APR, and showed that IL-6 
is an essential component in determining clinically relevant 
systemic responses such as anorexia, loss of body weight, and 
hypoglycemia. In contrast, only minor differences were de- 
tected in the same responses to LPS, demonstrating that IL-6 
is in this case dispensable. 
The finding that IL-6 is not required to generate in infhm- 
matory response to LPS was somewhat surprising,  as 1I.-6 
is produced in large quantities upon LPS injection (9). Pre- 
sumably its activity can be substituted for by other cytokines, 
in particular IL-1 and TNF-o~. It is interesting to note that 
LPS induced threefold higher TNF-c~ levels in IL-6-/-  mice 
than in the IL-6 + /+ controls; compensation through an in- 
creased TNF-c~ production might therefore account, at least 
partially, for the overall normal inflammatory reaction to LPS 
we observed in the IL-6-/-  mice. This idea is further cor- 
roborated by the fact that turpentine abscesses, which do not 
elicit a normal response in the absence of IL-6, failed to in- 
duce TNF-o~ production.  Moreover,  the  most  prominent difference detected in the liver APR to LPS was the complete 
lack of induction of the o~2M RNA,  the only one among 
those analyzed belonging to class 2 AP genes, which respond 
neither  to IL-1 nor  to TNF (10). 
It has been recently shown that  IL-6, LIE  OM,  IL-11, 
and CNTF have remarkably overlapping functions, including 
the induction of the same range of APPs (11), because they 
all share the same signal transducing molecule, gp130 (40). 
Moreover, in vivo administration of LIF (41) and CNTF (42) 
can induce changes in the expression of acute phase genes. 
These cytokines have therefore been proposed to play an im- 
portant physiological role in the regulation of the APR. Our 
results, however, would not seem to support this idea:  the 
ot2M  gene,  known  to  be  responsive  to  several  IL-6-1ike 
cytokines, failed to be induced by either LPS or turpentine 
in the IL-6-/-  mice, and the overall response to localized 
inflammation was profoundly modified in the absence of IL-6. 
Although it is possible that different experimental protocols 
might produce different results, in our conditions the physi- 
ological contribution of IL-6-related cytokines is apparently 
negligible. Possible explanations for these results are that these 
cytokines might  not be produced  at the levels  required to 
elicit an appreciable response, or that the site of production 
might  not be appropriate for them  to reach target  organs 
such as the liver. 
Although IL-6 has been shown to synergize with IL-1 in 
the induction of the HPA axis (17), we found that CS induc- 
tion is not defective in the IL-6-/-  mice (Fig.  5, a and b). 
We have shown that CNTF is equivalent to IL-6 in elidting 
CS induction when co-injected with IL-1 (Fantuzzi,  G., manu- 
script submitted for publication). We propose therefore that 
CNTF and/or  some other cytokine bdonging  to the IL-6 
family are physiologically involved in the stimulation of the 
HPA axis,  thus rendering  IL-6 function dispensable. 
IL-6 has been proposed as playing a role in the pathogen- 
esis of several diseases,  including rheumatoid arthritis,  mul- 
tiple myeloma (reviewed in reference 43), and osteoporosis 
(21, 44). We have shown that IL-6 is required for several aspects 
of the inflammatory response to sterile tissue damage, which 
can be commonly caused by surgery or burns.  Although 
chronic or excessive liver APR, anorexia, and weight loss can 
contribute to morbidity,  these body responses are thought 
to be part of the host defense reactions to acute inflamma- 
tion. APPs include several protease inhibitors and heme-binding 
proteins,  which can limit  the damage at the site of injury 
and preserve the iron reserves of the organism, and mobiliza- 
tion of body fat and lean tissue may provide the substrates 
and energy required for tissue repair and recovery. IL-6, being 
an essential mediator of these responses,  might therefore exert 
a protective effect during  acute inflammation. 
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